[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
March 6, 2002

New Indication for Gleevec

Author Affiliations
 

Not Available

Not Available

JAMA. 2002;287(9):1103. doi:10.1001/jama.287.9.1103-JFD20003-2-1

The FDA has approved imatinib mesylate capsules (Gleevec, Novartis Pharmaceutical Corp, East Hanover, NJ), an approved treatment for chronic myeloid leukemia, for the treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

The new indication was approved on the basis of an open-label, randomized study in 147 patients with unresectable or metastatic malignant GIST who were randomized to receive either 400 mg or 600 mg of the drug daily for up to 24 months. Primary evidence of efficacy was based on objective response rates.

First Page Preview View Large
First page PDF preview
First page PDF preview
×